Evidence map›Paper›PMID 31145054›Full record

ArticleThe Journal of general virology2019

HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.

Terumasa Ikeda, Amy M Molan, Matthew C Jarvis, Michael A Carpenter, Daniel J Salamango, William L Brown, Reuben S Harris

Open access · greenAbstract read
In one paragraph

Article in The Journal of general virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Terumasa Ikeda2 Institute for Molecular Virology, Minneapolis, MN 55455, USA.
Amy M Molan4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Matthew C Jarvis3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
Michael A Carpenter3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
Daniel J Salamango1 Department of Biochemistry, Molecular Biology, and Biophysics, Minneapolis, MN 55455, USA.
William L Brown4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Reuben S Harris3 Center for Genome Engineering, Minneapolis, MN 55455, USA.
University of Minnesota · US

Funding

TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Minnesota Craniofacial Research Training ProgramT90DE022732 · NIDCR · UNIVERSITY OF MINNESOTA · PI MANSKY, KIM CARPENTER · 2012 to 2023
$4.9M
APOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
APOBEC3 STRUCTURAL STUDIESR01GM118000 · NIGMS · UNIVERSITY OF MINNESOTA · PI AIHARA, HIDEKI, HARRIS, REUBEN S · 2016 to 2019
$2.2M
The APOBEC in APOBEC mutagenesisF31CA243306 · NCI · UNIVERSITY OF MINNESOTA · PI JARVIS, MATTHEW C · 2019 to 2021
$94k
NCI NIH HHS F31 CA243306NCI NIH HHS T32 CA009138NIAID NIH HHS R37 AI064046NIAID NIH HHS T32 AI083196NIDCR NIH HHS T90 DE022732NIGMS NIH HHS R01 GM118000
6 · The paper itself

Abstract

HIV-1 replication in CD4-positive T lymphocytes requires counteraction of multiple different innate antiviral mechanisms. Macrophage cells are also thought to provide a reservoir for HIV-1 replication but less is known in this cell type about virus restriction and counteraction mechanisms. Many studies have combined to demonstrate roles for APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H in HIV-1 restriction and mutation in CD4-positive T lymphocytes, whereas the APOBEC enzymes involved in HIV-1 restriction in macrophages have yet to be delineated fully. We show that multiple APOBEC3 genes including APOBEC3G are expressed in myeloid cell lines such as THP-1. Vif-deficient HIV-1 produced from THP-1 is less infectious than Vif-proficient virus, and proviral DNA resulting from such Vif-deficient infections shows strong G to A mutation biases in the dinucleotide motif preferred by APOBEC3G. Moreover, Vif mutant viruses with selective sensitivity to APOBEC3G show Vif null-like infectivity levels and similarly strong APOBEC3G-biased mutation spectra. Importantly, APOBEC3G-null THP-1 cells yield Vif-deficient particles with significantly improved infectivities and proviral DNA with background levels of G to A hypermutation. These studies combine to indicate that APOBEC3G is the main HIV-1 restricting APOBEC3 family member in THP-1 cells.

Indexed as

APOBEC-3G DeaminaseHIV-1HIV InfectionsHost-Pathogen InteractionsHumansMutationMyeloid CellsTHP-1 Cellsvif Gene Products, Human Immunodeficiency VirusVirus ReplicationAPOBEC-3G DeaminaseAPOBEC3G protein, humanvif Gene Products, Human Immunodeficiency VirusAPOBEC3GG to A hypermutationHIV-1 restrictionmyeloid cell line THP-1Vif

Identifiers

PMID31145054
PMCPMC7176283
OpenAlexW2947935325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.